Objective: The aim of this study was to explore the relationship of PET/CT parameters with human papillomavirus (HPV) status of oropharyngeal (OP) and oral cavity (OC) squamous cell carcinomas (SCCs). Patients and Methods: We retrospectively reviewed 39 patients with OC and OP-SCC who underwent staging 18 F-FDG PET/CT. PET/CT parameters were measured for the primary tumor and the hottest involved node, including SUV max , SUV mean , SUV peak , metabolic tumor volume, total lesion glycolysis, standardized added metabolic activity (SAM), and normalized SAM. Patient characteristics were compared between HPV positive (HPV+) and negative (HPV−) groups. Receiver operating characteristic analysis was used to dichotomize PET/CT parameters into high and low. Logistic regression models predicting HPV status were fit for each PET/CT parameter. Results: The HPV+ group was composed of 18 patients all with OP-SCC; the HPV− group consisted of 21 patients, 4 OP cancer patients and 17 OC cancer patients. The HPV+ group had a higher proportion of N2 stage (94% vs 43%; P < 0.001). Nodal PET/CT parameters were higher in the HPV+ group (P < 0.01); this difference was not present for the primary lesion. After adjusting for sex and age, the association of higher nodal SUV max (odds ratio [OR], 9.67), SUV mean (OR, 10.48), SUV peak (OR 9.67), metabolic tumor volume (OR, 14.52), total lesion glycolysis (OR, 11.84), and SAM, normalized SAM (OR, 16.21) with HPV+ status remained statistically significant (P < 0.05). Conclusions: Nodal PET/CT parameters predict HPV status. High nodal FDG uptake should raise suspicion for positive HPV status in the evaluation of the primary lesion.
S quamous cell carcinoma of head and neck (SCCHN) is the sixth most common cancer with more than 50,000 new cases diagnosed each year. [1] [2] [3] Tobacco use, alcohol consumption, and human papillomavirus (HPV) infection are the best known risk factors associated with SCCHN. 4, 5 With the decrease in smoking prevalence in the past decade, there has been a decline in the incidence of oral cavity (OC), laryngeal carcinoma, and hypopharyngeal carcinoma in the United States 6 ; however, there has been a steady increase in incidence of HPV+ oropharyngeal (OP) squamous cell carcinomas (OP-SCCs). 7 The typical HPV+ OP-SCC patient is a white man, nonsmoker or infrequent smoker, and is younger than the average HPV− OP-SCC patient. Human papillomavirus-associated OP-SCC has a better prognosis than the non-HPV-associated OP-SCC. 4, 5 There has been substantial research evaluating biological and clinical behavior of HPV+ OP-SCCs, although research regarding imaging characteristics has been limited. 18 F-FDG PET/CT imaging has been increasingly used in the assessment of SCCHN. PET/CT provides both functional and anatomic information that offers significant improvement in diagnostic accuracy both in the pretreatment and posttreatment setting. Functional data from PET/CT can also provide quantitative information, which can be used as biomarkers that may have prognostic and diagnostic value. [8] [9] [10] [11] [12] [13] [14] SUV max , the most commonly used PET parameter, is the maximum SUV for a voxel in PET volume of interest (VOI). SUV mean is the average SUVof all the voxels in VOI PET. 15 SUV peak is the local average of a 1-mL spherical volume centered on SUV max and has been proposed to be less impacted by image noise and more reproducible than SUV max because it is not calculated from a single voxel. 13, 16 The role of SUV peak in head and neck carcinomas has not yet been studied. 13 Metabolic tumor volume (MTV, the volume of the tumor defined by metabolism instead of anatomical imaging) is the volume of VOI PET . Total lesion glycolysis (TLG) is the product of MTV and SUV mean and thus as a marker, incorporates both the tumor's size and activity. 9, 13, 14 Each of these parameters has limitations in practice. SUV max and SUV peak are subject to partial volume errors in small tumors, where the maximum pixel count in the PET scan varies with the distribution size and shape. 17, 18 SUV mean , MTV, and TLG will vary with the method used to determine the VOI PET , whether it be a gradient method as in this work, a contour based on a percentage of the maximum voxel value, or a manually drawn contour. For example, a larger VOI PET around the same tumor will increase the MTV and result in a decrease in SUV mean .
A recently reported measurement, standardized added metabolic activity (SAM), seeks to determine the total metabolic activity above background due to tumor uptake while avoiding partial volume effects and the influence of VOI size. 12 The goal in calculating SAM is to measure all of the activity due to the tumor in the measurement above the activity concentration of surrounding tissue. Although partial volume effects reduce the maximum voxel counts in small tumors, the total counts due to a given tumor should be linear with total activity.
Although OC-SCC and OP-SCC differ in etiology, cumulatively they form most of head and neck carcinomas. 19 The recent rise in number of OC-SCCs could be related to misclassification of some of OP-SCCs. 19 In advanced cases referred for PET/CT imaging, it can be even more challenging to identify the primary site due to presence of tumor both in OP and OC regions. 19, 20 The primary aim of this study was to explore the relationship of quantitative PET/CT parameters of primary tumor and regional nodal metastasis with HPV status in OC and OP-SCC. If a relationship between nodal PET/CT parameters and HPV status is present, the quantitative characteristics of nodal disease may also be useful to identify the primary site of origin between these 2 very different but anatomically very close and difficult to separate head and neck carcinoma subtypes.
PATIENTS AND METHODS

Patients
After institutional review board approval for this retrospective investigation, we performed a review of medical charts from January 2008 to March 2013 for treatment-naive patients with biopsy-proven SCCHN who had had a baseline PET/CT as well as at least 1 followup imaging study (either PET/CT or dedicated neck CT) examination performed in our institution.
Chart review targeted patient information, including any current or prior history of smoking and alcohol use, age at the time of diagnosis, ethnic origin, and sex; the primary malignancy subsite, original clinical TNM staging, and HPV status of the tumor; as well as the dates of treatment and treatment modality (chemotherapy, radiation therapy, surgery, or a combination thereof). Determination of the HPV status of the tumor at our institution was often done in a stepwise manner. The p16 immunohistochemical stain was completed first, and when interpreted as positive, HPV 16/18 in situ hybridization was subsequently completed to confirm evidence of transcriptionally active virus. When p16 immunohistochemical was negative, additional testing with HPV 16/18 in situ hybridization was not completed. 5 Patients with distant metastatic disease (M1) at initial presentation, aged younger than 18 years, or with a history of local and/or systemic therapy, including surgical intervention (excluding biopsy), before the baseline PET/CTwere excluded. Patients were also excluded if HPV status was unknown and in whom target tissues were not discretely separated from adjacent abnormal tissues.
FDG PET/CT Protocol
All PET/CT studies were performed using 1 of 4 PET/CT systems available in our department (GE Discovery 690 Elite, 600, ST, or LS; General Electric, Milwaukee, Wis). Patients fasted at least 4 hours before the scan and were imaged approximately 60 minutes after radiotracer injection. Scans were obtained from skull vertex to mid thigh with arms down. All PET data were reconstructed with and without CT-based attenuation correction. The emission scan lasted for 2 to 4 minutes for each bed position.
Image Analysis
All PET/CT studies were retrieved from the electronic archival system and reviewed on a MIMvista workstation (software version 6.1; MIM Software Inc) by 2 board-certified radiologists (A.T.K.K., A.C.), with subspecialty training in nuclear radiology/neuroradiology and in neuroradiology with expertise in head and neck imaging, respectively. PET and fused PET/CT images were reviewed in multiple planes. PET volume of interest was determined as the volume of hypermetabolic FDG uptake using a gradient technique from commercially available software (PETedge; MIM Software, Inc, Cleveland, Ohio).
The imaging biomarker measurements performed were SUV max , SUV mean , SUV peak , MTV, TLG, SAM, and normalized SAM (N-SAM). All SUVs used in this study are normalized to body weight (as opposed to body surface area or lean body mass). Once the primary tumor and/or regional nodal disease were segmented, SUV max , SUV mean , SUV peak , MTV, and TLG were automatically calculated by the MIMvista software for the primary lesion and for the hottest lymph node, or if there are many nodes with similar FDG activity, we chose the node with the largest axial dimension (Figs. 1, 2).
To calculate SAM, the VOI PET was determined as noted previously. A second VOI (VOI SAM ) was created by expanding VOI PET by 3 mm in 3 dimensions. VOI SAM should contain all of the counts due to the tumor but also includes some counts from surrounding tissue. A third VOI (VOI BKG ) was created by expanding VOI SAM , again by 3 mm, excluding other structures with high activity. Average SUV in the volume between VOI SAM and VOI BKG was calculated and used to subtract the SUVs that would be present in VOI SAM in the absence of tumor. Thus SAM represents the total SUVs above background for the tumor. Normalized SAM is calculated as SAM/(average normal tissue SUV) and seeks to remove errors due to some of the factors included in the SUV calculation such as scanner calibration and body weight. 12 The nodal PET/CT parameters were considered to be zero for patients with undetectable nodal disease at PET/CT.
Statistical Analysis
Statistical analysis was conducted using SAS Version 9.3. Descriptive statistics were reported for the total sample and also for each shows the primary VOI (red) and 2 outer VOIs (light blue and dark blue). SUV max , SUV mean , MTV, and TLG were calculated from VOI PET (defined by a gradient method using the PET uptake, pink contour). SUV peak was centered on the voxel defined by SUV max . SAM was calculated as the total SUVs from VOI SAM less the normal tissue SUVs calculated from the volume between VOI SAM (light blue) and VOI BKG (dark blue contour).
HPV group. Differences between groups were assessed using the χ 2 or Fisher exact test, where appropriate, for categorical variables and the analysis of variance for numeric variables. PET/CT parameters were first examined as continuous measures. Box plots were produced comparing the PET/CT parameters between the HPV+ and HPV− groups. To categorize the PET/CT parameters into 2 groups, a receiver operating characteristic (ROC) analysis was conducted to predict HPV status. The cut points that maximized sensitivity and specificity were chosen.
Logistic regression models predicting HPV status were fit separately for each PET/CT parameter. Firth penalized maximum like lihood estimation was used to reduce bias in the parameter estimates. Covariates that had a marginally significant association (P < 0.10) with HPV in unadjusted analysis were included in the models. However, N stage was excluded due to a strong collinearity with the nodal parameters.
RESULTS
Patient Characteristics
Thirty-nine patients met the eligibility and inclusion criteria. Patient demographics and tumor characteristics are listed in Table 1 . Twenty-eight patients were men, and 11 patients were women; the mean (SD) age was 64 (10.3) years. Thirty-seven patients were white, 1 patient was African American, and 1 patient was Indian.
Ten 
Associations With HPV Status
Patient characteristics were compared between HPV+ and HPV− patients. The HPV+ group was composed of 18 OP-SCC patients. The HPV− group consisted of 21 patients, 4 OP (4/21) and 17 OC-SCC. The HPV+ group had a higher proportion of males (89% vs 57%; P = 0.028) and N2 stage (94% vs 43%; P < 0.001) compared with the HPV− group (Table 1) . Those in the HPV+ group were also younger (59 vs 68; P = 0.003). All HPV+ patients were white.
Eleven patients did not have detectable nodal disease at PET/CT. The other 28 patients had both primary and nodal disease.
When comparing the PET/CT parameters between HPV groups, nodal PET/CT parameters (SUV max , SUV mean , SUV peak , TLG, MTV, SAM, and N-SAM) were significantly higher in the HPV+ group (P < 0.01), although this difference was not present for the primary lesion.
Because nodal quantitative values were noted to be significant, an ROC analysis was carried out, which demonstrates that with a nodal SUV max cutoff of 7.66, HPV positivity can be predicted with 83% sensitivity and 81% specificity. The cutoff values for all nodal PET/CT parameters and performance estimates are provided in Table 2 .
After adjusting for sex and age in the logistic regression models, the association of higher nodal SUV max (odds ratio [OR], 9.67), SUV mean 
DISCUSSION
In our study, we evaluated PET/CT parameters from analysis of FDG PET/CT of primary and regional nodal disease. We compared 2 groups-HPV+ and HPV−. We found that the HPV+ subgroup presents with more advanced N stage and high nodal PET/CT parameters (SUV max , SUV mean , SUV peak , TLG, MTV, SAM, and N-SAM), although this difference was not present for the primary lesion. After adjusting for sex and age, the association of higher nodal PET/CT parameters with HPV+ status remained statistically significant.
As the incidence of HPV+ OP-SCC increases, experience with imaging characteristics is also growing. Goldenberg et al 21 demonstrated an association with cystic/necrotic nodal metastasis with HPV + OP-SCCs. Recently, Cantrell et al 22 retrospectively reviewed pretreatment CT images of HPV+ and HPV− OP-SCC patients and mentioned that HPV+ OP-SCCs often had primary lesions with well-defined borders and "cystic" nodal metastasis, which is a well-known reason for false-negative results in PET/CT. 23 Recently, 2 publications explored associations between PET/CT findings and tumor HPV status. Joo et al 24 studied 78 patients with OP-SCC (28 HPV+ and 50 HPV−), and Tahari et al 25 studied 123 patients (98 HPV+ and 25 HPV−) with OP-SCC. Joo et al 24 found that a median SUV max value of 7.1 for the primary can be used as an adjuvant diagnostic tool for high-risk HPV infection, with a sensitivity of 78% and specificity of 68%. They also suggested that HPV negativity is associated with higher median SUV max of the primary tumor. Regional nodal disease was not evaluated in their study. Tahari et al 25 also revealed that HPV− primary tumors have higher PET/CT parameters, including morphologic and glycolytic indices. They noted higher PET parameters in HPV+ nodal metastasis, however, without statistical significance. In our investigation, we did not demonstrate a significant relationship between quantitative parameters for the primary lesion, but we did report a significant relationship for nodal parameters and HPV status. This discrepancy for significance of quantitative parameters for the primary lesion may be due to differences in patient populations in each study. Our finding of advanced nodal disease in HPV+ OP-SCCs is also in concordance with recent literature. 2, 26 Human papillomavirus p16 status is routinely determined for OP-SCC in our institution but not for non-OP-SCCHN because HPV + SCCHN in sites other than OP is still rare. A recent study by Combes and Franceschi 20 mentioned that the fraction of HPV+ OC-SCC is about 3%. Because of the possibility of having p16-positive cases in OC-SCC, we decided to obtain p16 assessment for our OC study population. None of our OC cases had p16 positivity, and they formed the majority of HPV− group in our study.
The OP-SCC group of our study was predominantly HPV+. The reason could be related to the fact that HPV+ OP-SCC patients mostly present with clinically detectable advanced nodal disease more than HPV− counterparts. Hence, PET/CT was mostly preferred as an imaging modality during staging of these patients due to presentation with advanced nodal disease. The other reason for a very high number of HPV+ cases in OP-SCC patients in this study could be related to demographics of our patient population. All of OP-SCCs patients were white in our study. Most of the OP-SCC patients were male. Because there is higher proportion of HPV+ OP-SCCs among white men, presence of a large number of HPV+ OP-SCCs in our study was expected. 19 There are recent reports questioning the prognostic value of advanced nodal disease in the era of HPV+ OP-SCC. 27 Because the immune system plays an important role in viral oncogenesis, current evidence supports that the improved prognosis in HPV+ cancers is attributable to a nearly intact cell cycle that is mildly disrupted by HPV oncoproteins and can be easily fixed after exposure to chemoradiation, unlike HPV− tumors. 6 The viral load is also correlated with higher failure rates, which may suggest that impaired immune regulation is a risk factor for poor outcome. 6 Therefore we suggest that the presence of large nodes with marked FDG activity may not reflect poor prognosis in HPV+ OP-SCCs and in fact could be a sign of a functionally intact and responding immune system with reactive changes, leading to high glycolytic activity to the nodal tissue, resulting in increased glycolytic indices in PET/CT. 13 PET/CT parameters should be interpreted cautiously in SCCHN, especially in OP-SCC by correlating with the HPV status of the patient. Although our study found an association between high nodal PET/CT parameters and HPV+ OP-SCCs, this will be only supportive to other findings and needs to be further evaluated.
Assessment of neck nodal disease with clinical carcinoma of unknown primary (CUP) with PET/CT is an accepted approach in clinical practice. 23 Most of the time, the CUP is localized to tonsils; however, there is marked variation in identifying the primary site by imaging. 23 Presence of cystic/necrotic cervical adenopathy is suggestive for HPV + OP-SCC, and this is a common reason for false negatives in PET/ CT. 23 In the absence of cystic/necrotic adenopathy, our finding of high nodal PET/CT parameters, specifically SUV max of 7.66 or higher in association with HPV+ OP-SCC, may be a useful tool when evaluating CUP cases as well by directing attention to the oropharynx. Although recent literature regarding CUP is somewhat contradictive, 28, 29 Vent et al 28 reported that p16-positive nodal disease in CUP is most likely to be OP-SCC. Limitations of our study include a relatively small patient population, retrospective analysis, as well as heterogeneity of PET scanners. In addition, the HPV− group was mostly composed of OC-SCCs. Prospective studies with larger patient populations are needed.
CONCLUSIONS
Presence of cervical nodal disease with a median SUV max of 7.66 or higher is suggestive for HPV+ OP-SCC. Recognition of regional nodal disease with high nodal FDG activity should not necessarily be interpreted as a bad prognostic factor in head and neck cancer. The benefits of recognizing imaging characteristics of HPV+ cases will become more important as new immunotherapies and deescalation treatments specific for this patient group are adopted.
In addition, in patients with CUP presenting with advanced nodal disease and high nodal PET/CT parameters, attention should be directed to OP sites in the search for the primary tumor because most of HPV+ cases originate from OP sites.
